W
William W. Busse
Researcher at University of Wisconsin-Madison
Publications - 740
Citations - 62685
William W. Busse is an academic researcher from University of Wisconsin-Madison. The author has contributed to research in topics: Asthma & Eosinophil. The author has an hindex of 115, co-authored 697 publications receiving 56703 citations. Previous affiliations of William W. Busse include National Institutes of Health & University at Buffalo.
Papers
More filters
Journal ArticleDOI
Obesity and asthma, an association modified by age of asthma onset
Fernando Holguin,Eugene R. Bleecker,William W. Busse,William J. Calhoun,Mario Castro,Serpil C. Erzurum,Anne M. Fitzpatrick,Benjamin Gaston,Elliot Israel,Nizar N. Jarjour,Wendy C. Moore,Stephen P. Peters,Michael A. Yonas,W. Gerald Teague,Sally E. Wenzel +14 more
TL;DR: Asthmatic subjects are differentially affected by obesity based on whether they had asthma early (<12 years of age) or later in life, and this results highlight the need to understand obesity as a comorbidity that affects specific clinical phenotypes and not all asthma subjects alike.
Journal ArticleDOI
A common cold virus, rhinovirus 16, potentiates airway inflammation after segmental antigen bronchoprovocation in allergic subjects.
TL;DR: It is concluded that rhinovirus upper respiratory infection significantly augments immediate and late allergic responses in the airways of allergic individuals after local antigen challenge, suggesting that one mechanism of increased asthma during a cold is an accentuation of allergic responses to the airway which may then contribute to bronchial inflammation.
Journal ArticleDOI
Evolution of dry powder inhaler design, formulation, and performance
S.P. Newman,William W. Busse +1 more
TL;DR: A well-designed DPI and an appropriate powder formulation can optimize the effectiveness of inhaled drug therapy and recent advances in formulation technology can increase lung dose and reduce its variability.
Journal ArticleDOI
Safety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti–IL-5 receptor α antibody, in a phase I study of subjects with mild asthma
William W. Busse,Rohit K. Katial,David Gossage,Suha Sari,Bing Wang,Roland Kolbeck,Anthony J. Coyle,Masamichi Koike,George L. Spitalny,Peter A. Kiener,Gregory P. Geba,Nestor A. Molfino +11 more
TL;DR: Single escalating doses of MEDI-563 had an acceptable safety profile and resulted in marked reduction of PB eosinophil counts within 24 hours after dosing, as well as C-reactive protein levels, which returned to baseline by study end.
Journal ArticleDOI
Mast Cell Phenotype, Location, and Activation in Severe Asthma: Data from the Severe Asthma Research Program
Silvana Balzar,Merritt L. Fajt,Suzy A. A. Comhair,Serpil C. Erzurum,Eugene R. Bleecker,William W. Busse,Mario Castro,Benjamin Gaston,Elliot Israel,Lawrence B. Schwartz,Douglas Curran-Everett,Charity G. Moore,Sally E. Wenzel +12 more
TL;DR: Severe asthma is associated with a predominance of MC(TC) in the airway submucosa and epithelium, and the data suggest an altered and active MC population contributes to SA pathology.